Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Conditions: Neovascular Age-Related Macular Degeneration Interventions: Genetic: LX102 subretinal injection; Biological: Aflibercept intravitreal injection Sponsors: Innostellar Biotherapeutics Co.,Ltd Recruiting

https://clinicaltrials.gov/study/NCT06196840

Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials

More News: Age-Related Macular Degeneration (AMD) | Gene Therapy | Genetics | Research